DJBL treatment improves glycaemic control and weight loss in type 2 diabetes and obesity, suggesting shorter duration may lower adverse events.
Background: Duodenal jejunal bypass liner (DJBL), also known as EndoBarrier or RESET (Morphic Medical, Boston, USA), is a 60 cm long impermeable fluoropolymer sleeve which is implanted by endoscopy into the first part of the small intestine where it remains for about 1 year. It is held in place by a nitinol anchor, such that food passes through it without coming into contact with the small intestine and promoting improved glycaemic control and weight loss in patients with type 2 diabetes and obesity. However, many serious adverse events (SAEs) occur during the final three months of treatment, suggesting that a shorter, 9-month implantation may reduce complications.
No takes yet. Share an insight, caveat, or question.
Schwacha et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: